{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-077950","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2025-04-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.776501+00:00","generated_at":"2026-05-23T17:24:13.531151+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Royalty Pharma appoints Vlad Coric, M.D., to Board of Directors effective April 7, 2025.","bullets":["Dr. Vlad Coric appointed to Royalty Pharma Board effective April 7, 2025.","He is Chairman and CEO of Biohaven, led Nurtec ODT approval and $13B sale to Pfizer.","Coric will stand for election at 2025 Annual Meeting; if elected, expected to join Compensation Committee.","Board determined Coric meets Nasdaq independence standards; will receive standard independent director compensation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-077950","json":"https://secwatch.observer/filing/0001193125-25-077950.json","markdown":"https://secwatch.observer/filing/0001193125-25-077950.md","text":"https://secwatch.observer/filing/0001193125-25-077950.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000119312525077950/0001193125-25-077950-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000119312525077950/d943352d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T17:24:13.531151+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7829fcd9e9","claim":"Vlad Coric was appointed as Director at Royalty Pharma plc.","evidence_excerpt":"Effective April 7, 2025, Dr. Vlad Coric was appointed to serve as a new member of the Board of Directors (the “Board”) of Royalty Pharma plc (the “Company”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802768/000119312525077950/0001193125-25-077950-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}